Tumor Necrosis Factor Alpha (TNF-α)
Tumor necrosis factor alpha (TNF-α), also known as cachectin and TNFSF1A, is the prototypic ligand of the TNF superfamily. It is a pleiotropic molecule that plays a central role in inflammation, apoptosis, and immune system development. TNF-α is produced by a wide variety of immune and epithelial cell types. Human TNF-α consists of a 35 amino acid (aa) cytoplasmic domain, a 21 aa transmembrane segment, and a 177 aa extracellular domain (ECD). The 26 kDa type 2 transmembrane protein is assembled intracellularly to form a noncovalently linked homotrimer. Ligation of this complex induces reverse signaling that promotes lymphocyte costimulation but diminishes monocyte responsiveness. TNF-α regulates lymphoid tissue development through control of apoptosis. It also promotes inflammatory responses by inducing the activation of vascular endothelial cells and macrophages.
TNF-α is a key cytokine in the development of several inflammatory disorders. It contributes to the development of type 2 diabetes through its effects on insulin resistance and fatty acid metabolism. TNF-α is also implicated in the development of inflammatory bowel diseases including ulcerative colitis and Crohn’s disease. In the tracheobronchial tissue, administration of TNF-α has shown to activate mast cells to release cysteinyl-leukotrienes LTC4 and LTD4 which are potent bronchoconstrictors and mediators of airway hyperresponsiveness, as in asthma. Clinical trials of TNF-α inhibitors have yielded promising results in the treatment of chronic inflammatory disorders such as rheumatoid arthritis, asthma, ulcerative colitis and Crohn’s disease.
- As an aid in diagnosis of inflammatory diseases and inflammation responses
- As an aid in diagnosis and management of type 2 diabetes
- As an aid in diagnosis and management of inflammatory bowel diseases
- As an aid in diagnosis and management of ulcerative colitis and Crohn’s disease
- As an ancillary test for asthma and asthma treatment
- As a marker for management of rheumatoid arthritis therapy
- It can serve to monitor infection and treatment
0-22 pg/mL
Serum collected in SST tubes, plain red, or plasma collected in green (lithium heparin).
Specimens should be frozen after serum/plasma separation (after 30 minutes).
- N Engl J Med. 2013 Aug 22;369(8):754-62. [PMID: 23964937]
- Dan Med J. 2012 Jul;59(7):C4480 [PMID: 22759856]
- Curr Opin Pharmacol. 2007 Jun;7(3):279-82 [PMID: 17475560]
- Am J Med Sci. 2003 Feb;325(2):75-92. [PMID: 12589232]
- Aust Fam Physician. 2007 Dec;36(12):1035-8. [PMID: 18075630]